Comparison of the clinical profile of Parkinson's disease between Spanish and Cameroonian Cohorts

Cubo, Esther; Jacques, Denis; Martinez‐Martín, Pablo; Rodríguez‐Blázquez, Carmen; Kuate, Callixte; Mariscal, Natividad; López, Irene Madroñal; Noubissi, Gustave; Mapoure, Yacouba Njankouo; Jon, Jean Louis; Mbahé, Salomon; Tchaleu, Benjamin Clet Nguenkam; Catalán, María-José

doi:10.1016/j.jns.2013.10.021

Cited by 20 publications

(24 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although evidence of this translocation has been generated in vitro in dopaminergic cell lines, the multiorgan expression of α -synuclein aggregates suggest the possibility of similar protein trafficking in other cell types. Finally, although the number of cases is small, the sample is representative of the patient population with PD who are treated in our hospital, and from which it was possible to observe, as previously reported by other authors, the predominance of males, something which was not observed in the case of AP 38,39. This finding is also an area of opportunity for future research.…”

Section: Discussionsupporting

confidence: 61%

α‐Synuclein inclusions in the skin of Parkinson's disease and parkinsonism

Rodríguez‐Leyva

Calderón-Garcidueñas

Jiménez‐Capdeville

et al. 2014

Ann Clin Transl Neurol

View full text Add to dashboard Cite

ObjectiveThe presence in the brain of α-synuclein containing Lewy neurites, or bodies, is the histological hallmark of Parkinson's disease (PD). The discovery of α-synuclein aggregates in nerve endings of the heart, digestive tract, and skin has lent support to the concept of PD as a systemic disease. Our goals were, first, to demonstrate the presence of α-synuclein inclusions in the skin and, second, to detect quantitative differences between patients with PD and atypical parkinsonism (AP).MethodsSkin biopsies were taken from 67 patients and 20 controls. The biopsies underwent immunohistochemistry (IHC) and immunofluorescence (IF) testing for α-synuclein, whereupon its presence was quantified as the percentage of positive cells. Patients were divided into those with PD and those with AP. AP patients included AP with neurodegenerative disease (proteinopathies) and secondary AP.ResultsSixty-seven patients (34 with PD) and 20 controls were recruited. In the PD group, α-synuclein was detected in 58% of the cells in the spinous cell layer (SCL), 62% in the pilosebaceous unit (PSU), and 58% in the eccrine glands (EG). The AP-proteinopathies group showed 7%, 7%, and 0% expression of α-synuclein, respectively. No expression was found in the skin of the control group.ConclusionsThe expression of α-synuclein in the skin was relatively high in the PD group, scarce in AP, and null for the individuals in the control group. While these findings require further confirmation, this minimally invasive technique may aid in the improvement of the accuracy of PD diagnoses.

show abstract

Section: Discussionsupporting

confidence: 61%

α‐Synuclein inclusions in the skin of Parkinson's disease and parkinsonism

Rodríguez‐Leyva

Calderón-Garcidueñas

Jiménez‐Capdeville

et al. 2014

Ann Clin Transl Neurol

View full text Add to dashboard Cite

show abstract

“…The report on the prevalence of neuropsychiatric symptoms from Korea [11] was similar to ours and to the reports from European countries [5,6]. In a direct comparison of Cameroonian cohort of PD patients, with an age, sex, and disease duration-matched Spanish cohort [Longitudinal Study of Parkinson's disease, ELEP]; Cubo et al (2014) showed that Cameroonians were more severely impaired in terms of motor, cognitive status, anxiety and depression, psychosis, somnolence, fatigue and pain, caregiver burden, and quality of life, while autonomic features, comorbidity, and nocturnal sleep problems were similar.…”

Section: Discussionsupporting

confidence: 85%

“…Also, cultural, social and family structure might be responsible for differences [7][8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Neuropsychiatric symptoms in Serbian patients with Parkinson's disease

Petrovic

Stefanova

Ziropadja

et al. 2016

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…Our data clearly demonstrate one of the major constraints (nonavailability) to providing high‐quality care along the continuum of severity and symptomatology of PD in our practice environment. In a comparative study of Cameroonian (central African) and Spanish (European) PD cohorts, Cubo and colleagues made the salient observation that the Cameroonian patients received treatment only intermittently, had a trend of receiving lower doses of l ‐dopa, less frequently used dopaminergic agonists (and, when used, ergot derivatives were the norm), and more frequently took anticholinergics instead . Their conclusion was that this translated to significantly more‐severe impairment in motor function and cognitive status and a higher burden of anxiety, depression, psychosis, somnolence, fatigue, pain, caregiver burden, and quality‐of‐life impairment …”

Section: Discussionmentioning

confidence: 99%

A Nationwide Survey of Parkinson's Disease Medicines Availability and Affordability in Nigeria

Okubadejo

Ojo

Wahab

et al. 2018

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background and Objectives Limited access to medicines can impact negatively on outcomes in people with Parkinson's disease (PD). The study objectives were to determine the availability and assess the affordability of antiparkinsonian medications in pharmacies across Nigeria. Methods This was a cross‐sectional nationwide study utilizing the World Health Organization/Health Action Initiative methodology. Strategically selected private‐ and public‐sector pharmacies in the six geopolitical zones of Nigeria were surveyed for availability of medicines for management of early and advanced PD. The nine categories were: levodopa/peripheral decarboxylase inhibitors, dopamine receptor agonists, monoamine oxidase type B inhibitors, anticholinergics, catechol‐o‐methyl transferase inhibitors, atypical antipsychotics, antidepressants, antidementia drugs, and miscellaneous (e.g., drugs for orthostatism, urinary incontinence, and sleep disturbance). Unaffordability was defined as paying more than 1 days' wages (>N600 or > US$1.67) for a standard 30‐day supply. Results One hundred twenty‐three pharmacies were surveyed (62 private [50.4%] and 61 public sector [49.6%]; range of 15–25 pharmacies in each geopolitical zone). Private exceeded public‐sector availability across all nine categories of PD medicines (P < 0.05). The most available medicines were dopamine receptor agonists (68.3%; predominantly ergot‐derived bromocriptine), anticholinergics (56.1%; mainly trihexyphenidyl), and l‐dopa formulations (48%; mainly 250/25 l‐dopa/carbidopa). Only two medications (trihexyphenidyl tablets and biperiden injection) were affordable. The average number of day's minimum wages for a 30‐day supply of PD medicines was 41.3 days (range, 1–371). Conclusions PD medicines access is limited in Nigeria. Strategies, including engagement of stakeholders to consider interventions to improve and prioritize PD medicines access, are urgently warranted.

show abstract

Comparison of the clinical profile of Parkinson's disease between Spanish and Cameroonian Cohorts

Cited by 20 publications

References 21 publications

α‐Synuclein inclusions in the skin of Parkinson's disease and parkinsonism

α‐Synuclein inclusions in the skin of Parkinson's disease and parkinsonism

Neuropsychiatric symptoms in Serbian patients with Parkinson's disease

A Nationwide Survey of Parkinson's Disease Medicines Availability and Affordability in Nigeria

Contact Info

Product

Resources

About